Previous Close | 4.0000 |
Open | 4.0000 |
Bid | 4.1200 x 2900 |
Ask | 4.1300 x 2200 |
Day's Range | 3.9200 - 4.1850 |
52 Week Range | 2.4900 - 5.5300 |
Volume | |
Avg. Volume | 4,015,462 |
Market Cap | 1.055B |
Beta (5Y Monthly) | 1.95 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3750 |
Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for MNKD
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
MannKind celebrates that the FDA has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder Tyvaso DPI™ production is underway at MannKind Corporation (Nasdaq: MNKD) in Danbury, Conn. On May 24, 2022, MannKind celebrated that the U.S. Food and Drug Administration (FDA) has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder. Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s innovative Technosphere® inhalation technology. MannKin
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will ring the opening bell at the Nasdaq stock exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq MarketSite at Times Square. The ceremony will begin at a